Cellebrite DI ( (CLBT) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Cellebrite DI’s stock has recently been influenced by positive developments, including platform expansion and a shift to a subscription-based model. Analysts from William Blair and J.P. Morgan have maintained Buy ratings, with J.P. Morgan raising its price target. This optimism is driven by Cellebrite’s new FedRAMP certification, enabling access to U.S. federal markets, and the strategic acquisition of CyTech, which is expected to expand its Federal Total Addressable Market. These factors, alongside strong projected revenue growth, have improved the outlook for the company’s stock.
More about Cellebrite DI
YTD Price Performance: 15.05%
Average Trading Volume: 1,523,262
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $5.19B
For further insights into CLBT stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.